We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Peter C. Burger is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 1985 |
Burger, Peter C. |
U10Activity Code Description:
To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between sponsoring institutions and participating principal investigators, and are usually conducted under established protocols. |
Cns Tumor Biology-Therapy
Seven institutions are concurrently submitting Grant Proposals to establish the Brain Tumor Cooperative Group (BTCG). That Organization will study the biology of malignant gliomas and perform clinical trials utilizing radiotherapy, chemotherapy, and interferon. Included will be studies of interstitial radiotherapy and chemotherapy delivered by the intracarotid route. A critical need for such a cooperative effort is 1) a consistent centralized pathology review of histologic diagnoses and 2) a postmortem assessment of treatments effects on the neoplasms and surrounding brain. Accordingly, histologic slides of surgical specimens from all patients will be reviewed in accord with published criteria to determine patient eligibility for BTCG Clinical Trials and the appropriate stratification for subsequent statistical analyses of survivals. Secondly, the effects of therapy on the neoplasm will be investigated by a detailed neuropathologic study of selected brains using whole brain sections and multiple labeled blocks. The findings will be correlated with clinical history, CT scans, and details of specific therapies. Issues of particular importance include a) the morphologic effects of recent therapies such as interstitial radiation, intracarotid BCNU, and interferon on malignant gliomas and b) the pathologic consequences on normal brain of new therapies for malignant gliomas or modifications of existing modalities that deliver drugs or radiation in high focal concentrations.
|
0.97 |
| 1986 — 1988 |
Burger, Peter C. |
U10Activity Code Description:
To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between sponsoring institutions and participating principal investigators, and are usually conducted under established protocols. |
Brain Tumor Cooperative Group Cns Tumor Biology Therapy
Seven institutions are concurrently submitting Grant Proposals to establish the Brain Tumor Cooperative Group (BTCG). That Organization will study the biology of malignant gliomas and perform clinical trials utilizing radiotherapy, chemotherapy, and interferon. Included will be studies of interstitial radiotherapy and chemotherapy delivered by the intracarotid route. A critical need for such a cooperative effort is 1) a consistent centralized pathology review of histologic diagnoses and 2) a postmortem assessment of treatments effects on the neoplasms and surrounding brain. Accordingly, histologic slides of surgical specimens from all patients will be reviewed in accord with published criteria to determine patient eligibility for BTCG Clinical Trials and the appropriate stratification for subsequent statistical analyses of survivals. Secondly, the effects of therapy on the neoplasm will be investigated by a detailed neuropathologic study of selected brains using whole brain sections and multiple labeled blocks. The findings will be correlated with clinical history, CT scans, and details of specific therapies. Issues of particular importance include a) the morphologic effects of recent therapies such as interstitial radiation, intracarotid BCNU, and interferon on malignant gliomas and b) the pathologic consequences on normal brain of new therapies for malignant gliomas or modifications of existing modalities that deliver drugs or radiation in high focal concentrations.
|
0.97 |
| 1996 — 2000 |
Burger, Peter C |
U01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Molecular Biomarkers in the Classification of Glimoas @ Johns Hopkins University |
1 |
| 1996 — 1997 |
Burger, Peter C |
U01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Molecular Biomarkers in the Classification of Gliomas @ Johns Hopkins University |
1 |
